FGF-2 and FGF-16 protect isolated perfused mouse hearts from acute doxorubicin-induced contractile dysfunction

Cardiovascular Toxicology

Volumn 13, Issue 3, 2013, Pages 244-253

  Sontag, David P ^a   Wang, Jie ^a   Kardami, Elissavet ^a,b   Cattini, Peter A ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b ST BONIFACE GENERAL HOSPITAL   (Canada)

Author keywords

Cardioprotection; Developed pressure; Doxorubicin; FGF 16; FGF 2; Mouse Langendorff preparation

Indexed keywords

CHELERYTHRINE; DOXORUBICIN; FIBROBLAST GROWTH FACTOR 16; FIBROBLAST GROWTH FACTOR 2; LACTATE DEHYDROGENASE; PROTEIN KINASE C;

ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME RELEASE; HEART CONTRACTION; HEART DISEASE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE ISCHEMIA; HEART PERFUSION; HEART PROTECTION; HEART VENTRICLE ENDDIASTOLIC PRESSURE; INOTROPISM; LACTATE DEHYDROGENASE BLOOD LEVEL; MEMBRANE DAMAGE; MITOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REPERFUSION INJURY;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; BLOOD PRESSURE; CARDIOTONIC AGENTS; CORONARY CIRCULATION; DOXORUBICIN; ENZYME ACTIVATION; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTORS; HEART DISEASES; L-LACTATE DEHYDROGENASE; MICE; MYOCARDIAL CONTRACTION; MYOCARDIAL REPERFUSION INJURY; PROTEIN KINASE C; RECOMBINANT PROTEINS; REPERFUSION INJURY; VENTRICULAR FUNCTION, LEFT;

EID: 84884290194     PISSN: 15307905     EISSN: 15590259     Source Type: Journal    
DOI: 10.1007/s12012-013-9203-5     Document Type: Article

References (58)

1. Park, H. C., Jung, S. H., Ahn, J. S., Kim, M. Y., Yang, D. H., Kim, Y. K., et al. (2012). Rituximab plus ifosfamide, carboplatin and etoposide for T-cell/histiocyte-rich B-cell lymphoma arising in nodular lymphocyte-predominant Hodgkin's lymphoma. Case Reports in Oncology, 5, 413-419.
2. Swystun, L. L., Mukherjee, S., & Liaw, P. C. (2011). Breast cancer chemotherapy induces the release of cell-free DNA, a novel procoagulant stimulus. Journal of Thrombosis and Haemostasis, 9, 2313-2321.
3. Zhao, X., Zhang, J., Tong, N., Liao, X., Wang, E., Li, Z., et al. (2011). Berberine attenuates doxorubicin-induced cardiotoxicity in mice. Journal of International Medical Research, 39, 1720-1727.
4. San Miguel, J. F., Mateos, M. V., Ocio, E., & Garcia-Sanz, R. (2012). Multiple myeloma: treatment evolution. Hematology, 17(Suppl 1), S3-S6.
5. Wang, Y., Gonzalez, M., Cheng, C., Haouala, A., Krueger, T., Peters, S., et al. (2012). Photodynamic induced uptake of liposomal doxorubicin to rat lung tumors parallels tumor vascular density. Lasers in Surgery and Medicine, 44, 318-324.
6. Aguilo, J. I., Iturralde, M., Monleon, I., Inarrea, P., Pardo, J., Martinez-Lorenzo, M. J., et al. (2012). Cytotoxicity of quinone drugs on highly proliferative human leukemia T cells: Reactive oxygen species generation and inactive shortened SOD1 isoform implications. Chemico-Biological Interactions, 198, 18-28.
7. Octavia, Y., Tocchetti, C. G., Gabrielson, K. L., Janssens, S., Crijns, H. J., & Moens, A. L. (2012). Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies. Journal of Molecular and Cellular Cardiology, 52, 1213-1225.
8. Peng, X., Chen, B., Lim, C. C., & Sawyer, D. B. (2005). The cardiotoxicology of anthracycline chemotherapeutics: Translating molecular mechanism into preventative medicine. Molecular Interventions, 5, 163-171.
9. Hong, H. J., Liu, J. C., Chen, P. Y., Chen, J. J., Chan, P., & Cheng, T. H. (2012). Tanshinone IIA prevents doxorubicin-induced cardiomyocyte apoptosis through Akt-dependent pathway. International Journal of Cardiology, 157, 174-179.
10. Ito, T., Muraoka, S., Takahashi, K., Fujio, Y., Schaffer, S. W., & Azuma, J. (2009). Beneficial effect of taurine treatment against doxorubicin-induced cardiotoxicity in mice. Advances in Experimental Medicine and Biology, 643, 65-74.
11. Kalay, N., Basar, E., Ozdogru, I., Er, O., Cetinkaya, Y., Dogan, A., et al. (2006). Protective effects of carvedilol against anthracycline-induced cardiomyopathy. Journal of the American College of Cardiology, 48, 2258-2262.
12. Kim, K. H., Oudit, G. Y., & Backx, P. H. (2008). Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway. Journal of Pharmacology and Experimental Therapeutics, 324, 160-169.
13. Jiang, Z. S., Srisakuldee, W., Soulet, F., Bouche, G., & Kardami, E. (2004). Non-angiogenic FGF-2 protects the ischemic heart from injury, in the presence or absence of reperfusion. Cardiovascular Research, 62, 154-166.
14. Detillieux, K. A., Sheikh, F., Kardami, E., & Cattini, P. A. (2003). Biological activities of fibroblast growth factor-2 in the adult myocardium. Cardiovascular Research, 57, 8-19.
15. Jiang, Z. S., Padua, R. R., Ju, H., Doble, B. W., Jin, Y., Hao, J., et al. (2002). Acute protection of ischemic heart by FGF-2: Involvement of FGF-2 receptors and protein kinase C. American Journal of Physiology. Heart and Circulatory Physiology, 282, H1071-H1080.
16. House, S. L., Bolte, C., Zhou, M., Doetschman, T., Klevitsky, R., Newman, G., et al. (2003). Cardiac-specific overexpression of fibroblast growth factor-2 protects against myocardial dysfunction and infarction in a murine model of low-flow ischemia. Circulation, 108, 3140-3148.
17. House, S. L., Branch, K., Newman, G., Doetschman, T., & Schultz Jel, J. (2005). Cardioprotection induced by cardiac-specific overexpression of fibroblast growth factor-2 is mediated by the MAPK cascade. American Journal of Physiology. Heart and Circulatory Physiology, 289, H2167-H2175.
18. Padua, R. R., Merle, P. L., Doble, B. W., Yu, C. H., Zahradka, P., Pierce, G. N., et al. (1998). FGF-2-induced negative inotropism and cardioprotection are inhibited by chelerythrine: Involvement of sarcolemmal calcium-independent protein kinase C. Journal of Molecular and Cellular Cardiology, 30, 2695-2709.
19. Padua, R. R., Sethi, R., Dhalla, N. S., & Kardami, E. (1995). Basic fibroblast growth factor is cardioprotective in ischemia-reperfusion injury. Molecular and Cellular Biochemistry, 143, 129-135.
20. Virag, J. A., Rolle, M. L., Reece, J., Hardouin, S., Feigl, E. O., & Murry, C. E. (2007). Fibroblast growth factor-2 regulates myocardial infarct repair: Effects on cell proliferation, scar contraction, and ventricular function. American Journal of Pathology, 171, 1431-1440.
21. Pasumarthi, K. B., Kardami, E., & Cattini, P. A. (1996). High and low molecular weight fibroblast growth factor-2 increase proliferation of neonatal rat cardiac myocytes but have differential effects on binucleation and nuclear morphology. Evidence for both paracrine and intracrine actions of fibroblast growth factor-2. Circulation Research, 78, 126-136.
22. Sheikh, F., Sontag, D. P., Fandrich, R. R., Kardami, E., & Cattini, P. A. (2001). Overexpression of FGF-2 increases cardiac myocyte viability after injury in isolated mouse hearts. American Journal of Physiology. Heart and Circulatory Physiology, 280, H1039-H1050.
23. Kardami, E., Detillieux, K., Ma, X., Jiang, Z., Santiago, J. J., Jimenez, S. K., et al. (2007). Fibroblast growth factor-2 and cardioprotection. Heart Failure Reviews, 12, 267-277.
24. Detillieux, K. A., Cattini, P. A., & Kardami, E. (2004). Beyond angiogenesis: The cardioprotective potential of fibroblast growth factor-2. Canadian Journal of Physiology and Pharmacology, 82, 1044-1052.
25. Liao, S., Bodmer, J. R., Azhar, M., Newman, G., Coffin, J. D., Doetschman, T., et al. (2010). The influence of FGF2 high molecular weight (HMW) isoforms in the development of cardiac ischemia-reperfusion injury. Journal of Molecular and Cellular Cardiology, 48, 1245-1254.
26. Kardami, E., Liu, L., Pasumarthi, S. K., Doble, B. W., & Cattini, P. A. (1995). Regulation of basic fibroblast growth factor (bFGF) and FGF receptors in the heart. Annals of the New York Academy of Sciences, 752, 353-369.
27. Bailly, K., Soulet, F., Leroy, D., Amalric, F., & Bouche, G. (2000). Uncoupling of cell proliferation and differentiation activities of basic fibroblast growth factor. FASEB J, 14, 333-344.
28. House, S. L., Melhorn, S. J., Newman, G., Doetschman, T., & Schultz Jel, J. (2007). The protein kinase C pathway mediates cardioprotection induced by cardiac-specific overexpression of fibroblast growth factor-2. American Journal of Physiology. Heart and Circulatory Physiology, 293, H354-H365.
29. Clarke, M. S., Caldwell, R. W., Chiao, H., Miyake, K., & McNeil, P. L. (1995). Contraction-induced cell wounding and release of fibroblast growth factor in heart. Circulation Research, 76, 927-934.
30. Kaye, D., Pimental, D., Prasad, S., Maki, T., Berger, H. J., McNeil, P. L., et al. (1996). Role of transiently altered sarcolemmal membrane permeability and basic fibroblast growth factor release in the hypertrophic response of adult rat ventricular myocytes to increased mechanical activity in vitro. Journal of Clinical Investigation, 97, 281-291.
31. Hotta, Y., Sasaki, S., Konishi, M., Kinoshita, H., Kuwahara, K., Nakao, K., et al. (2008). Fgf16 is required for cardiomyocyte proliferation in the mouse embryonic heart. Developmental Dynamics, 237, 2947-2954.
32. Lu, S. Y., Sontag, D. P., Detillieux, K. A., & Cattini, P. A. (2008). FGF-16 is released from neonatal cardiac myocytes and alters growth-related signaling: A possible role in postnatal development. American Journal of Physiology. Cell Physiology, 294, C1242-C1249.
33. Miyake, A., Konishi, M., Martin, F. H., Hernday, N. A., Ozaki, K., Yamamoto, S., et al. (1998). Structure and expression of a novel member, FGF-16, on the fibroblast growth factor family. Biochemical and Biophysical Research Communications, 243, 148-152.
34. Sofronescu, A. G., Jin, Y., & Cattini, P. A. (2008). A myocyte enhancer factor 2 (MEF2) site located in a hypersensitive region of the FGF16 gene locus is required for preferential promoter activity in neonatal cardiac myocytes. DNA and Cell Biology, 27, 173-182.
35. Sofronescu, A. G., Detillieux, K. A., & Cattini, P. A. (2010). FGF-16 is a target for adrenergic stimulation through NF-kappaB activation in postnatal cardiac cells and adult mouse heart. Cardiovascular Research, 87, 102-110.
36. Ng, W. A., Grupp, I. L., Subramaniam, A., & Robbins, J. (1991). Cardiac myosin heavy chain mRNA expression and myocardial function in the mouse heart. Circulation Research, 68, 1742-1750.
37. Wang, J., Nachtigal, M. W., Kardami, E., & Cattini, P. A. (2013). FGF-2 protects cardiomyocytes from doxorubicin damage via protein kinase C-dependent effects on efflux transporters. Cardiovascular Research. doi: 10.1093/cvr/cvt011.
38. Gewirtz, D. A. (1999). A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochemical Pharmacology, 57, 727-741.
39. Tokarska-Schlattner, M., Zaugg, M., da Silva, R., Lucchinetti, E., Schaub, M. C., Wallimann, T., et al. (2005). Acute toxicity of doxorubicin on isolated perfused heart: Response of kinases regulating energy supply. American Journal of Physiology. Heart and Circulatory Physiology, 289, H37-H47.
40. Nazeyrollas, P., Prevost, A., Baccard, N., Manot, L., Devillier, P., & Millart, H. (1999). Effects of amifostine on perfused isolated rat heart and on acute doxorubicin-induced cardiotoxicity. Cancer Chemotherapy and Pharmacology, 43, 227-232.
41. Pouna, P., Bonoron-Adele, S., Gouverneur, G., Tariosse, L., Besse, P., & Robert, J. (1995). Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: Comparison of new analogues versus doxorubicin. Cancer Chemotherapy and Pharmacology, 35, 257-261.
42. Sayed-Ahmed, M. M., Shaarawy, S., Shouman, S. A., & Osman, A. M. (1999). Reversal of doxorubicin-induced cardiac metabolic damage by l-carnitine. Pharmacological Research, 39, 289-295.
43. Tokarska-Schlattner, M., Lucchinetti, E., Zaugg, M., Kay, L., Gratia, S., Guzun, R., et al. (2010). Early effects of doxorubicin in perfused heart: Transcriptional profiling reveals inhibition of cellular stress response genes. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 298, R1075-R1088.
44. Ishibashi, Y., Urabe, Y., Tsutsui, H., Kinugawa, S., Sugimachi, M., Takahashi, M., et al. (1997). Negative inotropic effect of basic fibroblast growth factor on adult rat cardiac myocyte. Circulation, 96, 2501-2504.
45. Montaigne, D., Hurt, C., & Neviere, R. (2012). Mitochondria death/survival signaling pathways in cardiotoxicity induced by anthracyclines and anticancer-targeted therapies. Biochemistry Research International, 2012, 951539.
46. Koti, B. C., Vishwanathswamy, A. H., Wagawade, J., & Thippeswamy, A. H. (2009). Cardioprotective effect of lipistat against doxorubicin induced myocardial toxicity in albino rats. Indian Journal of Experimental Biology, 47, 41-46.
47. Barnabe, N., Marusak, R. A., & Hasinoff, B. B. (2003). Prevention of doxorubicin-induced damage to rat heart myocytes by arginine analog nitric oxide synthase inhibitors and their enantiomers. Nitric Oxide, 9, 211-216.
48. Montaigne, D., Marechal, X., Baccouch, R., Modine, T., Preau, S., Zannis, K., et al. (2010). Stabilization of mitochondrial membrane potential prevents doxorubicin-induced cardiotoxicity in isolated rat heart. Toxicology and Applied Pharmacology, 244, 300-307.
49. Mochly-Rosen, D., Wu, G., Hahn, H., Osinska, H., Liron, T., Lorenz, J. N., et al. (2000). Cardiotrophic effects of protein kinase C epsilon: Analysis by in vivo modulation of PKCepsilon translocation. Circulation Research, 86, 1173-1179.
50. Baines, C. P., Song, C. X., Zheng, Y. T., Wang, G. W., Zhang, J., Wang, O. L., et al. (2003). Protein kinase cepsilon interacts with and inhibits the permeability transition pore in cardiac mitochondria. Circulation Research, 92, 873-880.
51. Budas, G. R., & Mochly-Rosen, D. (2007). Mitochondrial protein kinase Cepsilon (PKCepsilon): Emerging role in cardiac protection from ischaemic damage. Biochemical Society Transactions, 35, 1052-1054.
52. Chen, L. W., Egan, L., Li, Z. W., Greten, F. R., Kagnoff, M. F., & Karin, M. (2003). The two faces of IKK and NF-kappaB inhibition: Prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nature Medicine, 9, 575-581.
53. Ryazantseva, N. V., Novitskii, V. V., Zhukova, O. B., Biktasova, A. K., Chechina, O. E., Sazonova, E. V., et al. (2010). Role of NF-kB, p53, and p21 in the regulation of TNF-alpha mediated apoptosis of lymphocytes. Bulletin of Experimental Biology and Medicine, 149, 50-53.
54. Siracusano, L., Girasole, V., Alvaro, S., & Chiavarino, N. D. (2006). Myocardial preconditioning and cardioprotection by volatile anaesthetics. Journal of Cardiovascular Medicine (Hagerstown, Md.), 7, 86-95.
55. Katamadze, N. A., Lartsuliani, K. P., & Kiknadze, M. P. (2009). Left ventricular function in patients with toxic cardiomyopathy and with idiopathic dilated cardiomyopathy treated with doxorubicin. Georgian Medical News, 43-48.
56. Kumar, S., Marfatia, R., Tannenbaum, S., Yang, C., & Avelar, E. (2012). Doxorubicin-induced cardiomyopathy 17 years after chemotherapy. Texas Heart Institute Journal, 39, 424-427.
57. Fontijn, D., Duyndam, M. C., Belien, J. A., Gallegoz Ruiz, M. I., Pinedo, H. M., & Boven, E. (2007). The 18 kDa isoform of basic fibroblast growth factor is sufficient to stimulate human melanoma growth and angiogenesis. Melanoma Research, 17, 155-168.
58. Das, A., Durrant, D., Mitchell, C., Mayton, E., Hoke, N. N., Salloum, F. N., et al. (2010). Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. Proceedings of the National Academy of Sciences of the United States of America, 107, 18202-18207.